Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness.
Age Factors
Ambulatory Care
/ methods
Child
Child, Preschool
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Incidence
Infant
Influenza A virus
/ immunology
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ epidemiology
Male
Respiratory Tract Infections
/ epidemiology
Retrospective Studies
Seasons
United States
/ epidemiology
Vaccines, Inactivated
/ administration & dosage
Journal
JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
pubmed:
5
5
2020
medline:
23
3
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
The burden of influenza among young children is high, and influenza vaccination is the primary strategy to prevent the virus and its complications. Less is known about differences in clinical protection following 1 vs 2 doses of initial influenza vaccination. To describe patterns of influenza vaccination among young children who receive outpatient care for acute respiratory tract illness in the US and compare vaccine effectiveness (VE) against medically attended laboratory-confirmed influenza by number of influenza vaccine doses received. This test-negative case-control study was conducted in outpatient clinics, including emergency departments, at 5 sites of the US Influenza Vaccine Effectiveness Network during the 2014-2015 through 2017-2018 influenza seasons. The present study was performed from November 5, 2014, to April 12, 2018, during periods of local influenza circulation. Children aged 6 months to 8 years with an acute respiratory tract illness with cough who presented for outpatient care within 7 days of illness onset were included. All children were tested using real-time, reverse-transcriptase polymerase chain reaction for influenza for research purposes. Vaccination in the enrollment season with either 1 or 2 doses of inactivated influenza vaccine as documented from electronic medical records, including state immunization information systems. Medically attended acute respiratory tract infection with real-time, reverse-transcriptase polymerase chain reaction testing for influenza. Of 7533 children, 3480 children (46%) were girls, 4687 children (62%) were non-Hispanic white, and 4871 children (65%) were younger than 5 years. A total of 3912 children (52%) were unvaccinated in the enrollment season, 2924 children (39%) were fully vaccinated, and 697 children (9%) were partially vaccinated. Adjusted VE against any influenza was 51% (95% CI, 44%-57%) among fully vaccinated children and 41% (95% CI, 25%-54%) among partially vaccinated children. Among 1519 vaccine-naive children aged 6 months to 2 years, the VE of 2 doses in the enrollment season was 53% (95% CI, 28%-70%), and the VE of 1 dose was 23% (95% CI, -11% to 47%); those who received 2 doses were less likely to test positive for influenza compared with children who received only 1 dose (adjusted odds ratio, 0.57; 95% CI, 0.35-0.93). Consistent with US influenza vaccine policy, receipt of the recommended number of doses resulted in higher VE than partial vaccination in 4 influenza seasons. Efforts to improve 2-dose coverage for previously unvaccinated children may reduce the burden of influenza in this population.
Identifiants
pubmed: 32364599
pii: 2765162
doi: 10.1001/jamapediatrics.2020.0372
pmc: PMC7199168
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-713Subventions
Organisme : NCRR NIH HHS
ID : UL1 RR024153
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000471
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000474
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000473
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001039
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000467
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001038
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000005
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000466
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Pediatrics. 2006 Sep;118(3):e570-8
pubmed: 16950948
MMWR Recomm Rep. 2016 Aug 26;65(5):1-54
pubmed: 27560619
J Infect Dis. 2014 Sep 1;210(5):674-83
pubmed: 24676207
J Pediatr. 2006 Dec;149(6):755-762
pubmed: 17137887
J Infect Dis. 2019 Oct 8;220(10):1568-1576
pubmed: 31290537
Pediatrics. 1999 Jun;103(6):e73
pubmed: 10353970
J Infect Dis. 2006 Oct 15;194(8):1032-9
pubmed: 16991077
Pediatr Infect Dis J. 2016 Mar;35(3):299-308
pubmed: 26658375
Pediatrics. 2000 Nov;106(5):973-6
pubmed: 11061762
Pediatrics. 2006 Dec;118(6):2409-17
pubmed: 17142526
MMWR Morb Mortal Wkly Rep. 2014 Aug 15;63(32):691-7
pubmed: 25121712
Clin Vaccine Immunol. 2011 Mar;18(3):469-76
pubmed: 21209157
Pediatrics. 2011 Aug;128(2):e276-89
pubmed: 21768314
N Engl J Med. 2000 Jan 27;342(4):225-31
pubmed: 10648763
Pediatrics. 2004 Jun;113(6):1758-64
pubmed: 15173503
MMWR Recomm Rep. 2017 Aug 25;66(2):1-20
pubmed: 28841201
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25
pubmed: 26247435
Clin Infect Dis. 2020 Jun 10;70(12):2496-2502
pubmed: 31344229
Clin Infect Dis. 2012 Oct;55(7):951-9
pubmed: 22843783
J Infect Dis. 2016 Oct 1;214(7):1010-9
pubmed: 27190176
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
Pediatrics. 2008 Nov;122(5):911-9
pubmed: 18977968
Clin Infect Dis. 2019 Nov 27;69(12):2153-2161
pubmed: 30753347
Arch Pediatr Adolesc Med. 2008 Oct;162(10):943-51
pubmed: 18838647
N Engl J Med. 2017 Aug 10;377(6):534-543
pubmed: 28792867
Pediatrics. 2006 Sep;118(3):e579-85
pubmed: 16950949
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1178-1181
pubmed: 29095809
Pediatrics. 2005 Jul;116(1):153-9
pubmed: 15995046